World Psoriasis Day (29th October)
- Psoriasis affects more than 125M worldwide. It can interfere with daily life and negatively impact social interaction.
- This disease has no cure, although effective treatments have been developed to ease the different signs and symptoms
- Many psoriasis sufferers state that their condition interferes with their capacity to enjoy life.2 In fact, this disease has a high psychological burden: 91% of psoriasis patients suffer from low self-esteem and 54% suffer from depression
In the framework of the World Psoriasis Day, which this year’s theme is “Breaking Barriers”, the International Federation of Psoriasis Association (IFPA) aims to raise awareness, fight prejudices and gain access to proper diagnosis for people with psoriasis. Almirall wants to join this purpose by launching ‘Not Today’, a story included in its project “Derma Stories”, which falls within the global “Shared Skin Initiative” campaign. The main aim of this scheme is to raise awareness of this dermatological conditions so that society can recognize the social and emotional impact this disease can cause in the quality of life of those patients and their families, as it affects more than 125 million people worldwide.
‘Not Today’ is the story of two young friends who are texting each other about going to a party for which they have both been preparing for months, however, one of the girls no longer feels like going to the party as she has a psoriasis outbreak.
Psoriasis can interfere with daily life and negatively impact social interaction and participation. Many psoriasis patients can become embarrassed about their condition and withdraw themselves from the outside world because of flaking, or scabs that may appear on their skin, alongside other symptoms. Furthermore, this illness has a high psychological cost because some of the worst effects of psoriasis are emotional: 91% of psoriasis patients suffer from low self-esteem issues and 54% suffer from depression.
According to a recent study conducted in the US, 98% of psoriasis patients reported that psoriasis impacted on their emotional life, 94% on their social life, 70% on family life, 68% on their professional career, 38% on physical functioning, 17% on sexual intimacy, and 21% on their educational life.
Many psoriasis sufferers state that their condition interferes with their capacity to enjoy life, demonstrating the extent to which psoriasis restricts quality of life. Other daily struggles faced by psoriasis patients include having to adapt clothing choices, bathing routine and sporting activities.
The lost opportunities and the burden from the disease over a significant portion of a lifetime can be cumulative and in many cases are irreversible. Furthermore, their inability to work due to psoriasis increases with psoriasis severity. Therefore, patients suffering from the severe form of the disease report a greater number of days absent from work or school.
In addition, psoriasis patients are frequently stigmatized and excluded from normal social environments, including schools, workplaces and swimming pools. As a result, they often avoid social activities and commonly report experiencing loneliness, isolation, feelings of being unattractive and frustration.
Psoriasis is a chronic immune disease that appears on the skin. It affects an estimated 7.5 million people in the U.S. and approximately 125 million people worldwide. It is a non-contagious disorder that speeds up the growth cycle of skin cells and results in thick scaly areas of skin. Psoriasis can be mild, moderate or severe. Mild psoriasis covers less than 3% of the body, its moderate form affects between 3-10% and severe psoriasis appears on more than 10% of the body.
The most common form of psoriasis, called plaque psoriasis, appears as red, raised areas of skin covered with flaky white scales, which may be itchy and painful and can crack and bleed. The disease can be associated with an inflammatory arthritis known as psoriatic arthritis. Despite existing treatment options, many people with plaque psoriasis continue to struggle with the ongoing, persistent nature of this chronic disease that often has a debilitating impact not only on their bodies but their everyday lives.
According to the World Health Organization (WHO), psoriasis is considered equally prevalent in both sexes. However, out of all studies that reported prevalence by sex, some studies indicated that psoriasis is more common in men, although quoted values are not statistically significant.
It is also important to emphasise that this disease can occur at any age (including children). However, some studies indicate that the average age of onset for psoriasis is around 33 years of age, and that 75% of cases occur before 46 years of age, while others suggest that onset is bimodal with two peaks of the disease (the first between 16 and 22 and the second between 57 and 60 years of age).
The International Federation of Psoriasis Associations (IFPA) is a non-profit organization made up of national and regional psoriasis associations from around the world.
IFPA strives to be the global psoriasis advocacy organization. Its goals are to empower IFPA’s members, improve living conditions for patients, raise awareness of psoriasis and psoriatic arthritis and cooperate with fellow stakeholders. Since its founding in 1971, IFPA has continuously sought to resolve the challenges facing the international psoriasis community.
Almirall is a global company based in Barcelona dedicated to providing valuable medicines and medical devices through its R&D, agreements and alliances. Our work covers the whole of the drug value chain. A consolidated growth allows us to devote our talent and efforts towards specialty areas and particularly to further grow as a leading Dermatology player. We are a specialist company, enabling us to accomplish the purpose of providing our innovative products wherever they are needed.
Founded in 1943, Almirall is listed on the Spanish Stock Exchange (ticker: ALM) and it has become a source of value creation for society due to its vision, and the commitment of its long-standing major shareholders. In 2015, Almirall revenues totaled 769 million euros and, with 1,800 employees, it has become a trusted presence across Europe, as well as in the US.
For more information, visit www.almirall.com.